Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102816 | 0.80 | CARM1 (0.50) | CARM1PRMT6DRD4GRIN2BGRIN1 | |
| SCHEMBL12110641 | 0.80 | CARM1 (0.50) | CARM1PRMT6DRD4GRIN2BGRIN1 | |
| SCHEMBL4864451 | 0.80 | CARM1 (0.61) | CARM1PRMT6DRD4MAOBOPRM1 | |
| SCHEMBL9079881 | 0.78 | CARM1 (0.41) | CARM1PRMT6DRD4GRIN2BGRIN1 | |
| SCHEMBL8096317 | 0.77 | CARM1 (0.50) | CARM1PRMT6DRD4DDB1CRBN | |
| SCHEMBL4696488 | 0.76 | MAOA (0.48) | CARM1PRMT6DRD4DDB1CRBN | |
| SCHEMBL576029 | 0.76 | MAOA (0.53) | CARM1PRMT6DDB1CRBNMAOA | |
| SCHEMBL13212034 | 0.76 | CARM1 (0.60) | CARM1PRMT6DRD4GRIN2BGRIN1 | |
| SCHEMBL3125608 | 0.76 | CARM1 (0.49) | CARM1PRMT6DRD4GRIN2BGRIN1 | |
| SCHEMBL5883656 | 0.75 | CARM1 (0.44) | CARM1PRMT6DDB1CRBNMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2205601-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050199-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| WO-1998016539-A1 | NOVEL THERAPEUTICALLY ACTIVE ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1998-04-23 | — | — | WO | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| US-5606065-A | ANTAGONIST OF NEUROKININ RECEIVERS | SANOFI (FR) | 1997-02-25 | — | — | US | disclosed |
| US-5589467-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1996-12-31 | — | — | US | disclosed |
| US-5578582-A | Methods of treating ischemia with C2, N6 -disubstituted adenosine derivatives | NOVO NORDISK A/S (DK) | 1996-11-26 | — | — | US | disclosed |
| EP-0719275-A1 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-07-03 | — | — | EP | disclosed |
| US-5432164-A | Anticonvulsants | NOVO NORDISK A/S (DK) | 1995-07-11 | — | — | US | disclosed |
| US-5411971-A | N-alkylenepiperidino compounds, their enantiomers and pharmaceutical compositions | ELF SANOFI (FR) | 1995-05-02 | — | — | US | disclosed |
| WO-1995007921-A1 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-03-23 | — | — | WO | disclosed |
| EP-0609375-A1 | NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-08-10 | — | — | EP | disclosed |
| WO-1993008206-A1 | NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | ADORA2A, ADORA1, ADORA3 | CARM1 2767/4885PRMT6 2293/4885DRD4 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.